In the past week, MRNS stock has gone down by -79.45%, with a monthly decline of -81.17% and a quarterly plunge of -82.81%. The volatility ratio for the week is 6.80%, and the volatility levels for the last 30 days are 6.72% for Marinus Pharmaceuticals Inc The simple moving average for the last 20 days is -80.56% for MRNS stock, with a simple moving average of -80.23% for the last 200 days.
Is It Worth Investing in Marinus Pharmaceuticals Inc (NASDAQ: MRNS) Right Now?
Moreover, the 36-month beta value for MRNS is 0.92. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MRNS is 50.81M and currently, short sellers hold a 6.84% of that float. On April 15, 2024, MRNS’s average trading volume was 443.91K shares.
MRNS) stock’s latest price update
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has seen a decline in its stock price by -77.59 in relation to its previous close of 7.52. However, the company has experienced a -79.45% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-05 that Start Time: 16:30 End Time: 17:36 March 1, 0000 ET Q4 2023 Earnings Conference Call March 05, 2024, 16:30 PM ET
Analysts’ Opinion of MRNS
Many brokerage firms have already submitted their reports for MRNS stocks, with Oppenheimer repeating the rating for MRNS by listing it as a “Perform.” The predicted price for MRNS in the upcoming period, according to Oppenheimer is $9 based on the research report published on August 11, 2023 of the previous year 2023.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see MRNS reach a price target of $23. The rating they have provided for MRNS stocks is “Outperform” according to the report published on January 20th, 2023.
Truist gave a rating of “Buy” to MRNS, setting the target price at $35 in the report published on September 30th of the previous year.
MRNS Trading at -81.80% from the 50-Day Moving Average
After a stumble in the market that brought MRNS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.04% of loss for the given period.
Volatility was left at 6.72%, however, over the last 30 days, the volatility rate increased by 6.80%, as shares sank -81.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -82.98% lower at present.
During the last 5 trading sessions, MRNS fell by -79.27%, which changed the moving average for the period of 200-days by -84.50% in comparison to the 20-day moving average, which settled at $8.28. In addition, Marinus Pharmaceuticals Inc saw -84.50% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRNS starting from Shafer Christina, who sale 2,153 shares at the price of $9.56 back on Feb 20 ’24. After this action, Shafer Christina now owns 60,308 shares of Marinus Pharmaceuticals Inc, valued at $20,583 using the latest closing price.
MANNING MARTHA E, the SVP, GEN. COUNSEL & CORP. SEC. of Marinus Pharmaceuticals Inc, sale 1,894 shares at $9.57 during a trade that took place back on Feb 20 ’24, which means that MANNING MARTHA E is holding 52,966 shares at $18,126 based on the most recent closing price.
Stock Fundamentals for MRNS
Current profitability levels for the company are sitting at:
- -4.24 for the present operating margin
- 0.93 for the gross margin
The net margin for Marinus Pharmaceuticals Inc stands at -4.56. The total capital return value is set at -1.01. Equity return is now at value -213.02, with -65.70 for asset returns.
Based on Marinus Pharmaceuticals Inc (MRNS), the company’s capital structure generated 0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -1.08. The debt to equity ratio resting at 6.54. The interest coverage ratio of the stock is -15.63.
Currently, EBITDA for the company is -130.93 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of 2.54. The receivables turnover for the company is 8.16for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.07.
Conclusion
To wrap up, the performance of Marinus Pharmaceuticals Inc (MRNS) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
